1 Title

4

5

11

12

18

36

- 2 Stromal Tumor Infiltrating Lymphocytes (sTILs) as a putative prognostic marker to identify
- a responsive subset of TNBC in an Indian Breast Cancer Cohort.

Authors:

- 6 Pooja M. Vaid, MSc^{1,2}, Anirudha K. Puntambekar, MBBS, MD³, Rituja A. Banale, BSc^{1,4},
- 7 Ruhi R. Reddy, B.Pharm^{1,4}, Rohini R. Unde, MSc in Clinical Research^{1,4}, Namrata P.
- 8 Namewar, MSc^{1,4}, Devaki A. Kelkar, PhD^{1,4}, LS Shashidhara, PhD,
- 9 FNA, FASc, FNASc^{1,2,5}, Chaitanyanand B Koppiker, MS in Oncosurgery^{1,4} and Madhura
- 10 Kulkarni, PhD^{1,4,*}.

Affiliations:

- ¹Centre for Translational Cancer Research: a joint initiative of Indian Institute of Science
- 14 Education and Research (IISER) Pune and Prashanti Cancer Care Mission (PCCM)
- Pune; ²Department of Biological Sciences, Ashoka University, Sonipat; ³Pathology
- Department, Ruby Hall Clinic Pune; ⁴Prashanti Cancer Care Mission Pune; ⁵Indian
- 17 Institute of Science Education and Research Pune.
- 19 *Corresponding author: <u>madhura.kulkarni@iiserpune.ac.in</u>
- 20 Madhura Kulkarni, PhD
- 21 Senior Scientist and DBT-Ramalingaswami Fellow
- 22 Centre for Translational Cancer Research.
- 23 Prashanti Cancer Care Mission, Pune and IISER Pune.
- 24 B-403, Third Floor, Main Building
- 25 Dr Homi Bhabha Road, Pashan, Pune 411 008
- 26 Maharashtra INDIA
- 27 Email: madhura.kulkarni@iiserpune.ac.in
- 28 Phone: +91-2025908099

29 Conflict of interest statement:

30 The authors declare no conflict of interest

31 Funding and Acknowledgement:

- 32 MK would like to acknowledge DBT- Ramalingaswami 're-entry' fellowship awarded by
- DBT-India. LSS would like to acknowledge DST-JC Bose Research Fellowship. Research
- grant to CTCR is supported by Bajaj Auto Ltd. PV would like to acknowledge Aditi Khatpe,
- Rutvi Shah and Dimple Adiwal for their help in standardization.

Running title:

- 38 Affordable prognostic marker to identify responsive TNBC
- 40 **Key words:** Stromal TILs, TNBC, Breast Cancer in India.
- 42 Abstract:

37

39

- 43 Objectives
- 44 Prognostic significance of stromal tumor infiltrating lymphocytes (sTILs) is evaluated to
- identify a responsive subset of TNBC in an Indian cohort of breast cancer patients.
- 46 Methods
- 47 A retrospective cohort of breast cancer patients from a single onco-surgeon breast cancer
- 48 clinic treated with uniform treatment strategy across is evaluated for sTILs. FFPE tissue
- of primary tumor of invasive breast carcinoma are collected with ethical approvals. Tumor
- sections blinded for subtypes are stained with H&E and scored for sTILs by a pathologist
- following Immuno-Oncology TILs working group's scoring guidelines.
- 52 Results
- 53 Analysis of 144 primary breast tumors for sTILs scores re-enforces significantly higher
- infiltration in TNBC tumors than HER2+ and ER+ tumors. Higher sTILs scores co-relate
- with gradually incremental pathological response to therapy specifically in TNBC subset
- and with better disease-free survival outcomes. Within TNBC, older and post-menopausal
- 57 patients harbor higher scores of sTILs.
- 58 Conclusion
- 59 Despite a small cohort of breast cancer patients, TNBC subtype reflected significantly
- 60 higher scores of sTILs with better response to therapy and disease-free outcomes as
- compared to other breast cancer subtypes. A larger number of breast cancer patients
- from an Indian cohort will strengthen the findings to establish sTILs as a marker to identify
- a responsive subset of TNBC.

Key points:

65 Key point 1:

- 66 This is a first attempt to understand the significance of stromal tumor-infiltrating
- 67 lymphocytes in a breast cancer cohort from India, where higher recurrence and mortality
- 68 rates are observed.
- 69 Key point 2:
- 70 TNBC tumors show higher sTILs infiltration compared to non-TNBC patients. Higher
- sTILs scores within TNBC co-relates with better therapy response disease-free survival.
- 72 Key point 3:
- 73 Higher sTILs scores in TNBC tumors in an Indian cohort showed a novel and unique
- association with old age and post-menopausal patients.

INTRODUCTION

75

- Breast Cancer is the leading cause for cancer related deaths in India, with close to 50%
- mortality rate¹. Though there are effective treatments available for Breast Cancer, most
- targeted therapies are available for subtypes that express the molecular receptors ER,
- 79 PR and/or HER2. A subtype that lacks expression of these receptors; triple negative
- breast cancer (TNBC) cannot avail targeted therapy². With lack of targeted treatment,
- TNBC is an aggressive subset of breast cancer with higher rates of recurrence and lower
- 82 overall survival^{3,4}.
- Worldwide, the prevalence of TNBC is 10-12%^{5,6}, while in India, the prevalence of TNBC
- is reported to be significantly higher and up to 20-30%⁷⁻⁹. Moreover, the proportion of
- 85 TNBC that presents with aggressive clinicopathological features such as younger and
- pre-menopausal age at incidence, high grade is also higher in Indian population⁷. With
- 87 no targetable treatment and higher proportions of aggressive disease at incidence, TNBC
- 88 poses a clinical challenge in India.
- 89 As of now, prognostication of TNBC is guided by clinicopathologic features such as
- 90 tumour size, proliferative index, lymph node involvement as well as age and co-existing
- conditions. Standard treatment for TNBC includes neoadjuvant chemotherapy (NACT),
- 92 followed by surgery^{10–12}. TNBC is reported to show better response to NACT than ER+ve
- subtype i.e. 22% to 56% depending on the treatment regime used^{3,13,14}. Pathological
- complete response in TNBC subtype is associated with better disease free survival 13,14.
- Cases with residual disease have been shown to have a significantly higher chance of
- 96 recurrence within 1st three years of treatment and reduced overall survival^{14–16}.
- 97 Recent studies have revealed tumor infiltrating lymphocytes (TILs) to be a promising
- 98 prognostic marker to predict response to therapy, specifically in TNBC^{17–19}. Tumor
- 99 infiltrating lymphocytes are cytotoxic lymphocytes infiltrating into tumor and stromal
- regions as a host immune response to target cancer cells^{20,21}. Higher proportion of
- infiltrating lymphocytes, especially in the stroma co-operate with the exogenous therapy
- enhancing the anti-tumor effects of the therapy^{22,23}. Meta-analysis of 3770 patients with
- higher TILs scores predicted complete response to NACT in 50% of the TNBC patients
- and high TILs scores associated with better long-term survival over 3 years, emphasizing
- prognostic significance of TILs in TNBC^{24,25}.
- 106 With high proportion of TNBC in India, understanding TILs distribution and its association
- with response to therapy and disease outcome may help predict a subset that is
- 108 responsive and has better chance at disease free survival. If similar associations are
- 109 found as seen in meta-analysis of western cohorts. TILs evaluation may provide a
- promise to predict a responsive subset of TNBC in India. In addition, TILs are easy to
- assess on histopathology of tumor tissue biopsies thus can be cost-effective and easily
- employable prognostic tool especially for low-resource countries like India.
- Here we evaluate TILs with respect to clinicopathological features and outcomes of breast
- cancer patient cohort from a single surgeon and oncologist breast cancer unit in India. All
- the patients in the cohort have received similar treatment regimens and follow-up, giving

high confidence in uniformity regarding treatment strategies. Primary, pre-treatment tumor tissue of 144 breast cancer patients are scored for stromal TILs according to the guidelines provided by the International TILs working group²³. Association of TILs scores with clinicopathological features such as age at diagnosis, menopausal status, grade, tumor size, lymph node involvement and disease outcomes are evaluated. For patients that received NACT (n=35), response to therapy and its association with TILs scores is also evaluated.

Despite the size of the cohort, a significant association of high sTILs scores with TNBC subtype is observed. Higher sTILs scores co-relate with better response to therapy and better disease outcome specifically in TNBC compared to non-TNBC. sTILs analysis within TNBC reflected distinct distribution between young, pre-menopausal patients as compared to old and post-menopausal patients. Old, post-menopausal patients presented with higher sTILs scores. Detailed co-relation with various clinical parameters of TNBC in comparison to non-TNBC is reported here.

MATERIALS AND METHODS

- Patient tissue samples and meta-data: Formalin-fixed paraffin-embedded (FFPE) tissue samples and associated deidentified patient meta data are received from the clinic, following appropriate patient consent and ethical approval (dated 21st July 2018 #IECHR/VB/2018/016). Patients who were diagnosed at or underwent/are undergoing treatment at the clinic from 2012 up to 15th March 2019 are included in the study. Patient data, including diagnostic clinico-pathological data, type of therapy and post-treatment follow-up data up to last follow-up /recurrence date/death is compiled and digitized. All FFPE tissue blocks used are of primary (pre-treatment) tissue. Of the 144 FFPE tissue samples used in this study, 106 are prepared from core biopsy tissue. 61 samples are of the naive tumor tissue block prepared from surgically excised tissue. All surgery tissue used is from patients who did not receive neo-adjuvant therapy.
- Molecular subtypes are inferred based on patient immunohistochemistry reports. Samples are divided into ER+/HER-, HER+ and TNBC based on ER/PR expression and HER2 scores. ER+/HER- samples are with more than 1% ER expression and HER2 IHC score of 0, 1 or 2 and FISH-negative. Samples with IHC HER2 grade 3 or grade 2 FISH positive are taken as HER2+. Triple-negative samples are the ones with less than 1% ER and PR expression and HER2 IHC grade 1 or 2 and FISH-negative. Pre-treatment primary tumor tissue selection for these three molecular subtypes is described in the flowchart in Figure 1.
- For NACT, TNBC patients (n=14) were treated with Taxanes with or without an Anthracycline/Cyclophosphamide (AC) or 5-Fluoro-Uracil/AC regimen. ER+ patients (n=15) were treated with anti-estrogens such as Letrozole or Tamoxifen. For HER2 positive patients (n=6), AC followed by a Taxane with trastuzumab was administered.
- For ACT, most TNBC cases received AC + Taxane as adjuvant therapy, some cases received Fluorouracil in addition. For non-TNBC cases, HER2+ cases were

- 160 mostly treated with Trastuzumab with or without a Taxane, or FAC and
- 161 Taxane, some hormone positive HER2 cases received hormonal therapy
- 162 Hormone positive cases were mostly treated with hormone therapy or with
- an AC + Taxane regimen.
- 164 Response to NACT is computed for 33 out of 35 patients who underwent NACT. Post-
- NACT, response to treatment is calculated by comparing cTcN values with ypTyPN. In
- case of absence of residual tumor and absence of lymph node metastasis during
- pathological examination of surgically removed tissue i.e. ypT0N0 status, response is
- considered as pathologically complete response (pCR). The presence of residual tumor
- and/or lymph node metastasis in surgically removed tissue is referred as Residual
- disease (RD). Response in patients with residual disease is further subdivided into three
- categories partial, stable or progressive disease when compared to pre-treatment tumor
- size and lymph node positivity (stage). Partial response cases show downstaging, stable
- disease has no change in stage and progressive disease shows an increase in tumor size
- and/or lymph node positivity.

187

193

Histopathology of FFPE tissue blocks

- 176 FFPE blocks once selected are processed for histopathology. Tumor sections of 4-5 µm
- are obtained using Leica Microtome RM2255. Tissue slides are deparaffinized. Each slide
- is cleaned and stained with a drop of undiluted Hematoxylin solution (Delafield, 38803) in
- a humidifying chamber for 15 mins followed by 1% eosin (Qualigen Q39312). The slides
- are then gradually dehydrated in ethanol solutions followed by Xylene. Slides are
- 181 mounted in DPX (Q18404).

182 Imaging of histopathology slides

- All slides are imaged by OptraScan using OS-15 bright field digital scanner at 400X
- magnification. Images are viewed using the 'Image viewer' software provided by Optra.
- These are then converted to TIFF format and processed using Image Viewer Version
- 186 2.0.4 by OptraScan for scale bars.

Stromal Tumor Infiltrating Lymphocytes (sTILs) Scoring.

- TILs percent distribution within stroma surrounding the tumor tissue is assessed from
- 189 H&E stained histopathology section of pre-treatment primary tumor tissue. The scoring is
- done by a single pathologist (AP) according to the recommendations of The TILs Working
- 191 group²³. The pathologist was blinded to the clinical data as well as molecular subtypes of
- the tissue. For our study, only stromal TILs are scored and used for the analysis.

Statistical Analysis

- 194 All statistical analysis is done using GraphPad Prism v.5. Demographic table was
- prepared using IBM SPSS Statistics v. 21.0.0.0. Distribution of clinicopathological
- characteristics within the cohort and breast cancer subtypes is tested using 2x2 (2x4 in
- case of tumor size) Chi square contingency test. Mean age across subtypes is compared
- using unpaired two-tailed Student's t-test. Column statistics for sTILs are computed on
- 199 GraphPad Prism v.5 to calculate mean and SD/SE across each sub-category of clinical
- 200 characteristics. Significant difference in distribution between TNBC and on-TNBC sTILs

- 201 scores across clinicopathological characteristics is tested with one-way ANOVA followed
- by Tukey's Multiple Comparison Test. Statistical analysis is done using GraphPad Prism
- v.5 and graphs are plotted.
- Disease outcomes are computed as follows: disease free survival (DFS) is calculated as
- time in months from date of surgery till date of recurrence or last follow-up date. Overall
- survival (OS) is calculated as time in months from the diagnosis date (biopsy date) till last
- follow-up date or date of death due to disease. Kaplan-Meier survival plots for DFS and
- OS for up to 3-years follow-up time are plotted and survival probabilities are computed by
- Log-rank, Breslow and Tarone-Ware cores towards 3-year DFS and OS.
- Distribution of response to NACT and breast cancer subtypes is tested using 2x4 Chi
- square contingency test. Box plot for sTILs distribution across response to NACT i.e. pCR
- 212 and RD is plotted on GraphPad Prism v.5. Mean sTILs and SE for different response to
- NACT i.e. complete, partial, stable or progressive is computed and plotted by using
- 214 GraphPad Prism v.5. Mean sTILs for different response to NACT across breast cancer
- subtypes is calculated and plotted using GraphPad Prism v.5.

RESULTS

216

217

218

219

220

Breast Cancer Cohort Characteristics

- 221 Pre-treatment primary tumor tissues were identified for 144 patients from the biobank as
- described in Figure 1. Demographic and clinical characteristics of the entire cohort and
- according to their molecular subtypes (TNBC and non-TNBC) are presented in Table 1.
- Average age of the cohort of 144 breast cancer patients is 53 ± 12 years with a range
- from 28-86 years. TNBC patients (n=50) with mean age of 50, showed equal distribution
- within young (< 50 years) and late (> 50 years) age. ER+ve (n=55) and HER2+ve (n=39)
- patients presented higher mean age of 56 and 54 years with higher proportion (69% and
- 64%; respectively) in late age category. 62% TNBC patients presented at postmenopausal age, and menopausal status is not significantly different across the
- subtypes. ER+ and HER2+ patients show significantly higher proportion of low grade
- 231 (89% and 62%; respectively) tumours, while TNBC shows close to equal distribution
- within low and high tumor grade (45% and 55%). Other than grade, tumor size (cT, pT),
- lymph node status (cN, pN), lymph-vascular invasion (LVI) do not show significantly
- 234 different distribution across all three subtypes. Overall survival and disease free survival
- data is available for 131 patients, with average follow-up of two years ranging from 0
- months to 14.3 years, and median follow-up of 1.7 years.
- To assess tumor response to NACT, patients who received NACT prior to surgery are
- identified. Out of 144 patients, 35 (24%) had received neoadjuvant chemotherapy (NACT)
- according to their molecular subtypes as described in 'Methods' section. Of these 35, 8
- patients show complete pathological response (pCR) as assessed by vpT0vpN0 status.

Stromal TILs Scores Distribution Across Clinical Parameters

- 242 Stromal TILs (sTILs) distribution score is evaluated for each tissue sample from H&E
- stained histopathology slide. Table S1A depicts the distribution of sTILs percent
- 244 distribution across clinical features of the cohort. Average sTILs scores show even
- 245 distribution across age, menopausal status, and lymph node status. Tumor grade and
- tumor size (cT and pT) show significantly skewed sTILs distribution where higher grade
- 247 and larger size tumors are associated with higher sTILs percentages^{26–28}.

Stromal TILs Scores and Co-relation with Molecular Subtypes

- 249 sTILs scores are compared between TNBC, ER+ve and HER2+ve tumor tissue.
- Representative images of each histopathology sections for each subtype are shown in
- Figure 2A. TNBC tumors harbor wider range of sTILs scores (5 90%) as compared to
- other subtypes (0-60% and 0-70% for ER+ve and HER2+ve tumors) as shown in the box
- plot (Figure 1B). Mean sTILs score is significantly higher in TNBC (35.02 ± 3.93, n=50)
- 254 compared to ER+ve and HER2+ve tumors (11.02 \pm 1.49, n = 55 and 21.64 \pm 3.17, n =
- 39). sTILs scores are binned into three categories: Low (<10%), Moderate (10-40%) and
- 256 High (> 40%) (Figure S1A) according to International TILs Working Group 2014 guidelines
- for TILs evaluation²³. Binned scores also reflect significantly skewed distribution between
- TNBC and other two subtypes. Less than 5 and 10% of ER+ve and HER2+ve samples
- refelct high TILs scores while close to 40% of TNBC tumors harbor high TILs scores.
- 260 (Figure S1B).

241

248

- sTILs scores are compared between the subtypes according to their clinical parameters
- (Table 2). Older age (>50) TNBC tumors reflect significantly higher proportion of sTILs
- scores compared to ER2+patients; 38.72 ± 5.83 , n=25 vs 10.74 ± 1.43 , n=38 respectively
- (Table 2 and Figure 2A). As expected, post-menopausal TNBC patients show significantly
- 265 higher proportion of sTILs scores as compared to ER2+ve patients; 37.86 ± 5.39,n=29 vs
- 10.08 ± 1.42, n=36 respectively (Table 2 and Figure 2B). No significant difference was seen
- across mean sTILs between HER2+ve and TNBC patients. Overall distribution of sTILs
- through low and high grades across subtypes is significantly different with high grade
- TNBC tumors presenting with higher mean sTILs score; 42.56 ± 5.70 (n=27), followed by
- 270 high-grade HER2+ve patients; 31.00 ± 5.35 (n=15) and ER+ve patients; 17.50 ± 3.59 (n=6).
- 271 (Figure 2C). Mean sTILs scores across clinical (cT) and pathological (pT) tumor size,
- lymph node (cN and pN) status showed higher scores for larger and lymph node negative
- tumors, specifically in TNBC as compared to non-TNBC subtypes (Figure 3D-G).
- Similarly, sTILs scores are significantly higher in LVI negative TNBC tumors as compared
- 275 to ER+ve tumors (33.73 \pm 5.27, n=30 vs 11.05 \pm 1.79, n=39) as represented in box graph
- 276 (Figure 3H).

277

sTILs Scores and response to NACT

- Out of 144 breast cancer patients, 35 patients received NACT. For 33 patients, pre and
- post-surgery records were available for cTcN and ypTypN data. ypT0ypN0 was taken as
- pathologically complete response (pCR). Out of 33, 8 patients show pCR post-NACT.
- Patients with complete response show wider range of sTILs scores compared to the rest
- who had residual disease (RD) post-NACT (n=25) (Figure 4A). For the patients with

residual disease, their response to NACT is further segregated into 'partial response' when the tumor is down staged by therapy, 'stable disease' when no change in the stage occurred post-NACT, and progression in the stage after NACT is taken as 'progressive disease' (Table S2). When sTILs scores are compared for each of these categories, inverse pattern is observed with treatment response. Patients with complete pathological response had highest mean sTILs scores of 30 ± 33 followed by partial response (22.90 \pm 19.96) and stable disease (14.36 \pm 15.60), and progressive disease with the least sTILs score of 5% (Figure 4B). sTILs scores for TNBC patients show similar gradual reduction for patients showing complete response (36.67 \pm 36.01), followed by partial response (25.80 \pm 26.23), and goes lower for patients with stable disease (10.00 \pm 8.66) (Figure 4F).

For the patients who received NACT, sTILs scores and response to NACT are further corelated across subtypes. TNBC patients who show complete pathological response had higher mean sTILs score (36.67%) compared to the rest (20%) (Fig 4E). Irrespective to the response to treatment, ER+ve and HER2+ve patients had lower mean sTILs scores (Figure 4C and 4D).

sTILs Scores and Disease Outcome

sTILs scores binned into three categories – low (<10%), moderate (10-40%) and high (>40%) are analyzed for association with the disease outcome using Kaplan Meier curves. The cohort shows no specific association of binned TILs scores with disease free survival (Figure 5A). When subtypes are segregated differing outcomes for disease free status with respect to binned sTILs scores is reflected depending on the subtype. High sTILs scores in TNBC tumors are associated with longer relapse free life as compared to low or moderate TILs scores, with hazard ratio of 0.49 by Cox regression (Figure 5D). On the other hand, high sTILs shows significantly poor survival in HER2+ve patients. (Figure 5C), while ER+ve patients show similar trend as TNBC patients. For overall survival, the cohort presented with 3 deaths due to disease, and all of which harbored moderate sTILs scores (Figure 6).

DISCUSSION

- This report is the first attempt to understand association of stromal TILs with clinicopathological features of breast cancer, their outcomes and response to therapy for an Indian cohort. The study is limited with a small cohort of 144 breast cancer patients, nevertheless the analysis confirms established association of sTILs with response to therapy and disease-free outcomes specifically in TNBC subtype. Further, this study brings forward significant co-relation of sTILs with clinicopathological features of TNBC subtype, perhaps specific to an Indian cohort.
- The cohort of 144 breast cancer that contained 50 TNBC, 55 ER+ve and 39 HER2+ve patients reflected uniform distribution of clinicopathological parameters except for age and grade. TNBC presented with younger mean age as compared to non-TNBC and comprised of higher proportion (50%) of young age (<50 years) and pre-menopausal

patients, unique to an India Breast Cancer Cohort^{7,9}. This is in contrast to the western cohorts where young age TNBCs present at 29-34%^{29,30}. TNBC in our cohort also presented with higher proportion of lower grade tumors (45%) as compared to western cohorts (20.2%)³¹. For patients who received NACT (n=33), 42.9% of TNBC patients had complete pathological response to the therapy as opposed to 7% and 20% of ER+ and HER2+ cohort. This is line with the current literature, where TNBCs indeed show better response to therapy^{3,13,14}.

Stromal TILs scores in the cohort were uniformly distributed irrespective of the clinicpathological parameters of the tumors, except for grade and tumor size. Higher grade and larger tumors showed significantly higher sTILs scores, as has been reported elsewhere^{27,32}. Subtype wise comparison of sTILs scores co-related well with reported studies²³ and meta-analysis²⁴, where TNBC subtype presented with wider sTILs scores distribution with a greater number of tumors with high sTILs scores (35%) as compared to ER+ and HER2+ subtypes (11% and 22% respectively). Within TNBC, higher sTILs scores co-related with better disease-free outcomes. With the limited number of patients that received NACT, broader and higher sTILs scores associated with complete pathological response. The gradual reduction in response to therapy with gradual decrease in sTILs scores was confined to TNBC subtype, similar to that has been reported in western population²⁴. The trends observed in our study are in line with the established association of sTILs distribution and TNBC outcomes, although not significant. Non-significant distribution patterns observed could be due to small cohort size or may be specific to Indian context, something that needs to be explored with larger cohort of breast cancer patients from India.

Apart from validating established associations of sTILs with disease outcome and response to therapy, our study uncovers unique associations of sTILs scores with clinicopathological features specifically in TNBC subtype. Significantly higher sTILs scores were observed for old age, post-menopausal TNBC patients as compared to young, pre-menopausal TNBC patients. This is in contrast to earlier reports, where a meta-analysis of nine studies showed significantly lower sTILs scores for older age²⁵. While in a cohort of 897 TNBC patients, no significant difference in sTILs scores was noted between old and young age TNBC patients³³. It is known in the field that young age TNBC patients, although with aggressive disease show better response to therapy and higher rates of pCR than older age TNBC patients^{34,35}. Whether, higher sTILs scores in older age, post-menopausal TNBC patients of our cohort translates into better response to therapy and better disease outcome for them needs to be further analysed with a larger cohort. Perhaps such association could possibly turn out to be specific to TNBC in an Indian context.

Further analysis for sTILs distribution will provide validation to establish TILs as a predictive tool to segregate old age post-menopausal TNBC patients who may benefit from NACT and young age, pre-menopausal TNBC patients with aggressive disease who are most likely to be non-responders to the therapy.

REFERENCES:

- 1. International Agency for Research on Cancer (IARC). GLOBOCAN 2018: Latest global cancer data. *CA Cancer J Clin*. 2018.
- Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast. *J Clin Oncol*. 2013;31(31):3997-4013. doi:10.1200/JCO.2013.50.9984
- Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. *J Clin Oncol*. 2008;26(8):1275-1281. doi:10.1200/JCO.2007.14.4147
- Kassam F, Enright K, Dent R, et al. Survival outcomes for patients with metastatic
 triple-negative breast cancer: Implications for clinical practice and trial design. *Clin Breast Cancer*. 2009;9(1):29-33. doi:10.3816/CBC.2009.n.005
- Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive Analysis of Estrogen Receptor (ER) - and HER2-Negative Invasive Breast Cancer, the so-Called Triple-Negative Phenotype: A Population-Based Study from the California Cancer Registry. 2007;(March). doi:10.1002/cncr.22618
- Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. *Cancer*. 2012;118(22):5463-5472. doi:10.1002/cncr.27581
- Kulkarni A, Kelkar D., Parikh N, Shashidhara LS, Koppiker CB, Kulkarni M. Meta analysis of prevalence of Triple Negative Breast Cancer and its clinical features at incidence in Indian Breast Cancer Patients. JCO Glob Oncol. 2020;In press.
- Sandhu GS, Erqou S, Patterson H, Mathew A. Prevalence of Triple-Negative
 Breast Cancer in India: Systematic Review and Meta-Analysis. *J Glob Oncol*.
 2016;2(6):412-421. doi:10.1200/jgo.2016.005397
- Thakur KK, Bordoloi D, Kunnumakkara AB. Alarming Burden of Triple-Negative
 Breast Cancer in India. *Clin Breast Cancer*. 2018;18(3):e393-e399.
 doi:10.1016/j.clbc.2017.07.013
- Mehanna J, Haddad FGH, Eid R, Lambertini M, Kourie HR. Triple-negative breast cancer: Current perspective on the evolving therapeutic landscape. *Int J Womens Health*. 2019;11:431-437. doi:10.2147/IJWH.S178349
- 401 11. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long 402 term clinical benefit in breast cancer: The CTNeoBC pooled analysis. *Lancet*.
 403 2014;384(9938):164-172. doi:10.1016/S0140-6736(13)62422-8
- Telli ML, Gradishar WJ, Ward JH. NCCN Guidelines Updates: Breast Cancer. *J Natl Compr Canc Netw.* 2019;17(55):552-555. doi:10.6004/jnccn.2019.5006
- Von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol*. 2012;30(15):1796-1804. doi:10.1200/JCO.2011.38.8595

- 14. Caparica R, Lambertini M, de Azambuja E. How I treat metastatic triple-negative breast cancer. *ESMO Open*. 2019;4(Suppl 2):e000504. doi:10.1136/esmoopen-2019-000504
- Sharma P, Lopez-Tarruella S, García-Saenz JA, et al. Pathological Response and
 Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus
 Docetaxel. Clin Cancer Res. 2018;24(23):5820-5829. doi:10.1158/1078 0432.CCR-18-0585
- 417 16. Symmans WF, Wei C, Gould R, et al. Long-Term Prognostic Risk After
 418 Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast
 419 Cancer Subtype. *J Clin Oncol*. 2017;35(10):1049-1060.
 420 doi:10.1200/JCO.2015.63.1010
- 17. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105-113. doi:10.1200/JCO.2009.23.7370
- Denkert C, Von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. *J Clin Oncol.* 2015;33(9):983-991. doi:10.1200/JCO.2014.58.1967
- 428 19. Castaneda CA, Mittendorf E, Casavilca S, et al. Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. World J Clin Oncol. 2016;7(5):387-394. doi:10.5306/wjco.v7.i5.387
- 431 20. Anichini A, Fossau G. Clonal analysis of the cytolytic T-cell response to human tumors. *Immunol Today*. 1987;8(No. 12):385-389. doi:10.1016/0167-5699(87)90215-5.
- 434 21. Naukkarinen A, Syrjänen KJ. Quantitative immunohistochemical analysis of 435 mononuclear infiltrates in breast carcinomas—correlation with tumour 436 differentiation. *J Pathol*. 1990;160:217-222. doi:10.1002/path.1711600307
- Khoury T, Nagrale V, Opyrchal M, Peng X, Yao S. Prognostic Significance of Stromal Versus Intratumoral Infiltrating Lymphocytes in Different Subtypes of Breast Cancer Treated with Cytotoxic Neoadjuvant Chemotherapy. *Appl Immunohistochem Mol Morphol*. 2018;(716):1-20.
 doi:10.1097/PAI.0000000000000466.Prognostic
- Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs
 Working Group 2014. *Ann Oncol*. 2015;26(2):259-271.
 doi:10.1093/annonc/mdu450
- Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. *Lancet Oncol.* 2018. doi:10.1016/S1470-2045(17)30904-X
- Loi S, Drubay D, Adams S, Pruneri G, Francis PA. Tumor-In fi Itrating
 Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage

- Triple-Negative Breast Cancers abstract. *Am J Clin Oncol.* 2019;37(7):559-570. doi:10.1200/JCO.18.01010
- 454 26. Miyoshi Y, Shien T, Ogiya A, et al. Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer.

 457 Oncol Lett. 2019;17(2):2177-2186. doi:10.3892/ol.2018.9853
- Kurozumi, Sasagu; Matsumoto, Hiroshi; Kurosumi, Masafumi; Inoue, Kenichi;
 Fujii, Takaaki; Horiguchi, Jun; Shirabe, Ken; Oyama, Tetsunari; Kuwano H.
 Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptornegative breast cancer without lymph node metastasis. *Oncol Lett*.
 2019;17(3):2647-2656. doi:10.3892/ol.2019.9938
- Sawe RT, Mining SK, Ofulla A V., et al. Tumor infiltrating leukocyte density is independent of tumor grade and molecular subtype in aggressive breast cancer of Western Kenya. *Trop Med Health*. 2017;45(1):1-11. doi:10.1186/s41182-017-0059-4
- Tano S V., Kavanaugh MM, Peddi P, Mansour RP, Shi R, Burton G Von. Triple negative breast cancer (TNBC): Analysis of age and stage distribution and survival between African American and Caucasian women in a predominant low-income population. *J Clin Oncol*. 2017. doi:10.1200/jco.2017.35.15_suppl.e12586
- 471 30. Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in breast cancer
 472 survival by molecular subtypes in the United States. *Cancer Epidemiol* 473 *Biomarkers Prev.* 2018;27(6):619-626. doi:10.1158/1055-9965.EPI-17-0627
- 474 31. Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR.
 475 Features of triple-negative breast cancer Analysis of 38,813 cases from the
 476 national cancer database. *Med (United States)*. 2016;95(35).
 477 doi:10.1097/MD.0000000000004614
- 478 32. Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: A pooled individual patient analysis of early-stage triple-negative breast cancers. *J Clin Oncol.* 2019. doi:10.1200/JCO.18.01010
- 481 33. Pruneri G, Vingiani A, Bagnardi V, et al. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. *Ann Oncol*. 2016;27(2):249-256. doi:10.1093/annonc/mdv571
- Loibl S, Jackisch C, Lederer B, et al. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials. *Breast Cancer Res Treat*. 2015;152(2):377-387. doi:10.1007/s10549-015-3479-z
- Waldenfels G Von, Loibl S, Furlanetto J, et al. Outcome after neoadjuvant chemotherapy in elderly breast cancer patients a pooled analysis of individual patient data from eight prospectively randomized controlled trials. *Oncotarget*. 2018;9(20):15168-15179. doi:10.18632/oncotarget.24586

Figure Legends

493 494

495

496

497

498

499

500 501

502

503

504 505

506 507

508

509

510

511

512

513

514

Figure 1: Flow chart to explain selection of primary breast cancer tissue.

Primary tumor tissue selection from retrospectively (2010-March 2019) collected PCCM biobank. Out of 653 patients breast tissues deposited with patient consent at PCCM biobank, 233 were of primary tumor (172 biopsy tissue and 61 naïve surgery tissue). Out of these, molecular subtypes were assigned for 185 for whom IHC reports were available. Out of 185, 144 tissue samples with good tissue integrity were sectioned, stained with H&E and then scored for stromal tumor infiltrating lymphocytes following International TILs working group guidelines.

Table 1: Demographic and clinical features of breast cancer patient cohort.

Number of patients with breast cancer were grouped into , ER+/PR+/PR-/HER2- , HER2+ and TNBC. The number of patients are listed according to the clinical variables reported at the time of diagnosis as per both the subtypes. Clinical parameters such as age at diagnosis, menopausal status, tumour grade and radiological tumor size, lymph node positivity and LVI are listed. For patients who did not receive NACT/NAHT, pT and pN retrieved from the surgery pathology report are noted. For patients who received NACT/NAHT, pathological response to the therapy is noted based on their ypTN status. Total number of patients with follow-up and time to follow-up and follow-up status are also noted. Any skewed distribution of clinical parameters in the cohort was tested using the 2*3 (4*3 in case of tumor size) $\chi 2$ contingency test with GraphPad Prism v.5. Red font indicates significant p-values

- indicates significant p-values
 *For comparing mean age differences among the subtypes, 1-way ANOVA was used.
- LVI- lympho-vascular invasion, Neo-adjuvant chemotherapy (NACT), pCR- pathological
- 518 complete response.

Figure 2: sTILs distribution across all three subtypes tumor tissue.

- A. Images depicting stromal TILs distribution. Representative images of sTILs scores for
- 521 ER+(left panel), HER2+(middle panel) & TNBC (right panel). Percent sTILs score for each
- of the tissue is mentioned on the figure. Blue lines are the scale bars representing 200um.
- **B.** Box plot shows distribution of sTILs scores across ER+, HER2+ and TNBC tumor
- tissue. The horizontal line represents median. Error bars represent Tukey's whiskers. The actual number of patient samples (n) are shown in the box plot. The distribution of the
- 526 sTILs scores between tissue samples across each subtype was tested for statistical
- significance with Student's t-test, using GraphPad Prism v.5. * represents p-value <0.05,
- ** represents p-value <0.01, and *** represents p-value <0.0001.

Table 2: Mean sTILs scores with respect to clinicopathological features of breast cancer subtypes.

- Mean ± S.E sTILs scores across clinicopathological parameters including age at
- 532 diagnosis, menopausal status of patients, tumor grade, radiological and pathological
- tumor size and lymph node status and LVI according to the molecular subtypes are
- 534 presented.

- 535 The statistical analysis was done in GraphPad Prism v.5. One-way ANOVA was
- performed to compute significant difference in mean sTILs scores between breast
- cancer subtypes and for comparing mean sTILs scores across each category and
- 538 subtypes.
- Red font indicates significant p-values.
- *LVI- lympho-vascular invasion
- Figure 3. sTILs distribution across clinico-pathological parameters with respect to
- 542 **subtypes.**
- Box plots depicting mean sTILs scores for ER+, HER2+ and TNBC tumor tissue across
- A. early & late age, B. pre & post-menopausal status, C. low (I/II) and high (III) grade
- 545 tumors, **D.** clinical tumor size; T1 and T2, **E.** clinical lymph-node status positive and
- negative, **F.** pathological tumor size; T1 and T2, **G.** pathological lymph-node status –
- positive and negative, **H.** LVI status positive & negative. The number of tissue samples
- (n) are shown on top of each bar. Error bars represent Tukey's whiskers.
- 549 Unpaired t-test was performed to test for significance across each parameter between
- 550 individual subtypes. Only grade shows significant differences across all three subtypes,
- which is represented here. p-value <0.05 is represented with '*', <0.01 with '**' and,
- 552 <0.0001 with '***'. ns= non-significant. GraphPad Prism v.5 was used for the graphs and</p>
- 553 ANOVA test.
- Figure 4: Mean sTILs scores and its association with response to NACT.
- A. sTILs score distribution is plotted for patients who showed complete pathological
- response (pCR) or had residual disease (RD) post-NACT. Box plots with horizontal lines
- show median sTILs score and The horizontal line represents, and error bars represent
- Tukey's whiskers. Mean sTILs across both groups are not significantly different as tested
- by two-tailed unpaired t-test. B. Box plot representing mean sTILS score for all the
- patients that received NACT and showed either complete orpartial pathological response
- or had a stable or progressive disease at the time of surgery. Error bars represent Tukey's
- whiskers. **C.** Mean sTILs scores for ER+ patients who had pCR or residual disease (RD).
- No statistics could be computed. Error bars represent Tukey's whiskers. **D.** Mean sTILs
- scores for HER+ patients who had pCR or residual disease (RD). No statistics could be
- 565 computed. Error bars represent Tukey's whiskers. E. Mean sTILs scores for TNBC
- patients who had pCR or residual disease (RD). Unpaired t-test was run for sTILs score
- across pCR and RD. Error bars represent Tukey's whiskers. **F.** Box plot representing
- mean sTILS score only for TNBC patients that received NACT and showed either
- complete or partial pathological response or had a stable or progressive disease at the
- time of surgery. Error bars represent Tukey's whiskers.
- *pCR-pathological complete response, RD-Residual disease
- Figure 5: Three year disease-free survival with respect to binned sTILs scores.
- 573 Disease free survival was calculated as number of months from the date of surgery till the
- recurrence diagnosis date or last follow-up date. The cut-off for DFS calculation was taken

at 3- years and calculated for a total of 131 patients. Kaplan-Meier survival plots for disease-free survival (DFS) according to low, moderate & high sTILs score bins for A. the entire cohort, B. ER+ patients and C. HER2+ patients and D. TNBC patients. In the graph, X-axis represents time scale in months, Y-axis represents the survival probability. Bluelines indicate patients with low sTILs score, red-line indicates patients with moderate score & green indicates high sTILs scores. Each drop shown as vertical line represents an event i.e. local or distant recurrence. Survival probability with respect to sTILs binned scores is tested using IBM SPSS Statistics v. 21.0.0.0.

Figure 6: Three year overall survival with respect to binned sTILs scores.

Overall survival was calculated as number of months from the date of biopsy till the last follow-up date. The cut-off for OS calculation was taken at 3- years and calculated for a total of 137 patients. Kaplan-meier survival plots showing overall survival (OS) of patients according to low, moderate & high sTILs score bins for A. the entire cohort and B. ER+ patients and C.TNBC patients. In the graph, X-axis represents time scale in months, Y-axis represents the survival probability. Blue-line indicates patients with low sTILs score, red-line indicates patients with moderate score & green indicates high sTILs scores. Each drop shown as vertical line represents an event i.e. death due to disease. Survival probability for each factor is tested by using IBM SPSS Statistics v. 21.0.0.0.

Supplementary Legends:

Table S1: Mean sTILs scores with respect to clinical features of the cohort.

Mean ± S.E of sTILs scores across clinicopathological parameters including age at diagnosis, menopausal status of patients, tumor grade, radiological tumor size and lymph node status and LVI. For comparing mean TILs score differences across each parameter two-tailed, unpaired t-test was performed on GraphPad Prism v.5.

#Red font indicates significant p-values.

* LVI- lympho-vascular invasion

Figure S1: Binned sTILs distribution across all breast cancer subtypes tumor tissue.

A. Representative images depicting stromal TILs distribution in tumor. Images of binned TILs scores are presented here for non-TNBC (left panel) & TNBC (right panel). Representative images of Low (<10%), Moderate (10%-39%) and High (>40%) sTILs scores as imaged on OptraScan at 10X magnification and processed using ImageViewer 2.0.4. Blue lines are the scale bars representing 200um.

B. Bar graph demonstrating percent frequency across binned categories of sTILs scores in ER+, HER2+ and TNBC subtypes. The number of patients in each bin (n) are shown on top of the bars. Association of categorical sTILs variable (Low, Moderate and High) across breast cancer subtypes was tested for significance by $3*3 \chi 2$ test using GraphPad Prism v.5.

Table S2: Response to NACT across breast cancer subtypes.

Number of patients treated with NACT and their response to NACT is recorded as complete, partial, no response as in stable disease or progressive disease. Number of patients in each response category for ER+, HER2+ and TNBC are given in the table. The distribution across subtypes for pCR status was tested using $\chi 2$ test and was found to be non-significant.

Figure 1: Flow chart to explain selection of primary breast cancer tissue





Table 1: Demographic and clinical features of breast cancer patient cohort


| | | ВС | ER+ | HER2+ | TNBC | p-values |
|----------------------------|-------------------------------|-------------|-------------|-------------|-------------|----------|
| No. of patients | | 144 | 55 | 39 | 50 | |
| Age (n=144) | (Mean ± S.D) | 53.4 ± 12.3 | 55.9 ± 12.4 | 54.2 ± 11.6 | 50.0 ± 12.2 | *0.0455 |
| | | 56 | 17(30.9%) | 14(35.9%) | 25(50%) | 0.1214 |
| | Late (≤ 50) | 88 | 38(69.1%) | 25(64.1%) | 25(50%) | |
| Menopausal | | 35 | 9(20%) | 8(21.6%) | 18(38.3%) | 0.0958 |
| status (n=129) | noct | 94 | 36(80%) | 29(78.4%) | 29(61.7%) | |
| Grade | | 92 | 46(88.5%) | 24(61.5%) | 22(44.9%) | < 0.0001 |
| (n=140) | 111311 (1117 | 48 | 6(11.5%) | 15(38.5%) | 27(55.1%) | |
| Tumor size | T1 | 35 | 21(40.4%) | 7(19.4%) | 7(15.2%) | 0.054 |
| (cT) (n=134) | | 93 | 28(53.9%) | 28(77.8%) | 37(80.4%) | |
| | Т3 | 4 | 2(3.8%) | 0(0%) | 2(4.4%) | |
| | T4 | 2 | 1(1.9%) | 1(2.8%) | 0(0%) | |
| LN status | negative | 59 | 25(53.2%) | 14(38.9%) | 20(43.5%) | 0.4011 |
| (cN) (n=129) | positive | 70 | 22(46.8%) | 22(61.1%) | 26(56.5%) | |
| pT (primary | | 5 | 3(9.7%) | 0(0%) | 2(6.1%) | 0.3852 |
| tissue, no NACT) | | 17 | 8(25.8%) | 4(12.9%) | 5(15.1%) | |
| (n=95) | T2 | 68 | 18(58.1%) | 26(83.9%) | 24(72.7%) | |
| | T3 | 4 | 1(3.2%) | 1(3.2%) | 2(6.1%) | |
| | T4 | 1 | 1(3.2%) | 0(0%) | 0(0%) | |
| pN (primary | negative | 65 | 23(74.2%) | 19(61.3%) | 23(69.7%) | 0.54 |
| tissue, no NACT) (n=95) | positive | 30 | 8(25.8%) | 12(38.7%) | 10(30.3%) | |
| LVI | negative | 95 | 39(76.5%) | 26(70.3%) | 30(71.4%) | 0.777 |
| (n=130) | positive | 35 | 12(23.5%) | 11(29.7%) | 12(28.6%) | |
| NACT | No | 106 | 37(71.2%) | 33(84.6%) | 36(72%) | |
| (n=141) | Yes | 35 | 15(28.8%) | 6(15.4%) | 14(28%) | |
| PCR status after | | 8 | 1(7.1%) | 1(20%) | 6(42.9%) | 0.0855 |
| NACT (n=33) | Nia raamamaa | 25 | 13(92.9%) | 4(80%) | 8(57.1%) | |
| | No. followed-up | 131 | 46 | 36 | 49 | |
| Survival outcomes | Time in Months Mean(range) | 25(0-172) | 20(0-84) | 28(0-172) | 28(1-132) | |
| | Median months | 19 | 12 | 26 | 20 | |
| | # Recurred (local, distant) | 11 | 3 | 2 | 6 | |
| | # Death due to disease | 3 | 0 | 0 | 3 | |

Table S1: Mean sTILs scores with respect to clinical parameters of the cohort

| | | Average sTILs score Mean ± S.E | p-values |
|-------------------|--------------------|-----------------------------------|----------|
| No. Of patients | (n=144) | 22.23 ± 1.90 | |
| Age | Early (<50) (n=56) | 22.52 ± 3.00 | 0.9041 |
| (n=144) | Late (≥ 50) (n=88) | 22.05 ± 2.46 | |
| Menopausal status | Pre (n=35) | 21.80 ± 3.93) | 0.8275 |
| (n=129) | Post (n=94) | 22.82 ± 2.44 | |
| Grade | I/II (n=92) | 15.46 ± 1.812 | < 0.0001 |
| (n=140) | III (n=48) | 35.81 ± 3.814 | |
| Tumor size (cT) | T1 (n=35) | 15.11 ± 2.34 | 0.0244 |
| (n=128) | T2 (n=93) | 25.39 ± 2.62 | |
| LN status(cN) | Positive (n=70) | 24.84 ± 3.10 | 0.9681 |
| (n=129) | Negative (n=59) | 22.22 ± 3.20 | |
| LVI | Positive (n=28) | 24.54 ± 4.32 | 0.4388 |
| (n=123) | Negative (n=95) | 20.76 ± 2.31 | |
| Tumor size (pT) | T1 (n=17) | 17.29 ± 4.86 | 0.3004 |
| (n=85) | T2 (n=68) | 23.76 ± 2.85 | |
| LN status(pN) | Positive (n=30) | 22.70 ± 3.92 | 0.908 |
| (n=95) | Negative (n=65) | 23.29 ± 2.96 | |

Figure 2: sTILs distribution across all three subtypes tumor tissue.






ER+

TNBC

HER2+

Subtypes

Figure S1: Binned sTILs distribution across all breast cancer subtypes tumor tissue.






Figure 3: sTILs mean scores compared across molecular subtypes




Table S2: Response to NACT across breast cancer subtypes

| | | Total | ER+ | HER2+ | TNBC | p- values |
|--------------------------------|---------------------|-------|-----|-------|------|--------------|
| Pos-NACT response (n=33) | Complete | 8 | 1 | 1 | 6 | |
| | Partial | 16 | 9 | 2 | 5 | |
| | Stable disease | 8 | 3 | 2 | 3 | 0.3552 |
| | Progressive disease | 1 | 1 | 0 | 0 | |

Figure 4: Mean sTILs scores and its association with response to NACT




Figure 5: Disease-free survival according to sTILs scores.




Figure 6: Overall survival according to sTILs scores.

